Some of the effects of the selective sigma ligand (+)pentazocine are mediated via a naloxone-sensitive receptor.
Recently, in an attempt to isolate the nonopioid sigma receptor, Su and colleagues purified a protein from rat liver and brain which appeared to resemble the original sigma opioid receptor as proposed by Martin in 1976, and for which the nonopiate sigma-1 ligand (+)pentazocine presents a high affinity. Previous in vivo electrophysiological studies from our laboratory have demonstrated that several selective sigma-1 ligands potentiate the neuronal response to NMDA. The goal of the present series of experiments was to assess the effects of some selective sigma-1 ligands on the potentiation of the NMDA response and to determine if this potentiation was mediated by the naloxone-sensitive sigma receptor. Extracellular unitary recordings from pyramidal neurons of the CA3 region of the rat dorsal hippocampus were obtained. The sigma-1 ligands BD 737, L 687-384, and JO-1784 (igmesine), administered intravenously at low doses, potentiated the NMDA response but the opiate antagonist naloxone failed to reverse this potentiation. However, the potentiation of the NMDA response induced by the sigma-1 ligand (+)pentazocine was suppressed by naloxone but not by the mu antagonist cyprodime hydrobomide, the kappa antagonist DIPPA nor by the delta antagonist naltrindole. (+/-) Cyclazocine, which presents a high affinity for the above-mentioned sigma-opiate receptor acted as an antagonist by suppressing the potentiation of the NMDA response induced by both JO-1784 and (+)pentazocine. These results suggest that the effects induced by some sigma-1 ligands may, in fact, be sensitive to naloxone while others may not. The original classification of sigma receptors as opiates might have been partly accurate.
Couture
S
S
University of Ottawa, Ottawa, Ontario, Canada.
Debonnel
G
G
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D002934:Cinnamates / Q000008:administration & dosage / Q000494:pharmacology; D003496:Cyclazocine / Q000008:administration & dosage / Q000494:pharmacology; D003514:Cyclohexylamines / Q000008:administration & dosage / Q000494:pharmacology; D003521:Cyclopropanes / Q000008:administration & dosage / Q000494:pharmacology; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D007275:Injections, Intravenous; D008297:Male; D016202:N-Methylaspartate / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000494:pharmacology*; D010423:Pentazocine / Q000008:administration & dosage / Q000494:pharmacology*; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology; D017966:Pyramidal Cells / Q000187:drug effects / Q000502:physiology; D011759:Pyrrolidines / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017480:Receptors, sigma / Q000819:agonists*
D002934:Cinnamates; D003514:Cyclohexylamines; D003521:Cyclopropanes; D018690:Excitatory Amino Acid Agonists; D009292:Narcotic Antagonists; D010880:Piperidines; D011759:Pyrrolidines; D017480:Receptors, sigma; C075567:BD 737; D009270:Naloxone; D016202:N-Methylaspartate; C090669:L 687384; D003496:Cyclazocine; D010423:Pentazocine; C065310:igmesine